Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT06952075
Recruiting
GR1803 Injection in Patients With RRMM
Phase 2 · China · 1 site
Registry update: 30 Apr 2025
NCT06988020
Recruiting
"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma
Not applicable · Belgium · 1 site
Registry update: 24 Apr 2026
NCT06871176
Recruiting
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
Not applicable · Canada · 1 site
Registry update: 1 Oct 2026
NCT06961669
Recruiting
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
Not applicable · China · 1 site
Registry update: 29 May 2025
NCT06717113
Recruiting
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Early phase 1 · China · 2 sites
Registry update: 6 Jun 2025
NCT07248176
Recruiting
Universal CAR-T Cell Therapy for MM
Not applicable · China · 1 site
Registry update: 1 Dec 2025
NCT06409767
Recruiting
Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.
Not applicable · France · 10 sites
Registry update: 24 Sept 2025
NCT06622005
Recruiting
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 · United States · 1 site
Registry update: 13 Aug 2026
NCT06793475
Recruiting
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
Not applicable · China · 2 sites
Registry update: 14 Aug 2025
NCT07445438
Recruiting
Feasibility of a Multi-omics Platform for Hematological Malignancies
Not applicable · Italy · 1 site
Registry update: 3 Mar 2026
NCT06421675
Recruiting
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Phase 2 · Canada · 6 sites
Registry update: 28 Sept 2026
NCT07249073
Recruiting
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Early phase 1 · China · 1 site
Registry update: 25 Nov 2025
NCT06880393
Recruiting
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
Phase 2 · China · 1 site
Registry update: 3 Aug 2025
NCT06785415
Recruiting
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Phase 1/2 · United States · 1 site
Registry update: 25 Jun 2026
NCT07214324
Recruiting
Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
Not applicable · Italy · 4 sites
Registry update: 23 Apr 2026
NCT06615479
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada, Switzerland, Czechia, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Hungary, Israel, Italy, Japan, South Korea, Netherlands, Norway, Poland, Portugal, Romania, Saudi Arabia, Sweden, Singapore, Taiwan, United States · 140 sites
Registry update: 29 Oct 2026
NCT06028087
Recruiting
Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
Not applicable · Italy · 1 site
Registry update: 14 Mar 2025
NCT06784167
Recruiting
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Not applicable · United States · 1 site
Registry update: 23 Sept 2026
NCT06758375
Recruiting
Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients
Phase 2 · Mexico · 1 site
Registry update: 20 Mar 2025
NCT07109323
Recruiting
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Phase 1/2 · China · 1 site
Registry update: 7 Aug 2025

Ordered by registry start date. Freshness and sponsorship never change the order.